These data indicated that BsAbs of anti-mPEG/anti-HER2 were able to actively target the HER2+ cancer cells, thereby facilitating enhanced HER2-LsbMDDs accumulation in HER2+ tumors to improve the therapeutic efficacy and minimize potential side effects as a result of a preferable biodistribution in tumor cells. This evidence concerns the gene ERBB2 and cancer.